[ @entity5753 in the treatment of XXXX ].

@entity1 @entity788 @entity1007 @entity231 @entity301 @entity5753 @entity412 @entity158 @entity165
In 9 clinics 177 @entity1 (68 @entity1 and 109 @entity1 ) aged 23-69 years with @entity1007 (TC above 6.5 mmol/L) were treated with @entity5753 for 12 weeks. The treatment was started with 20 mg daily. The dose was doubled every 4 weeks, if the total serum @entity165 level did not fall below 5.2 mmol/L. For 4 weeks before treatment with @entity5753 all @entity1 received placebo. After the first 4 weeks of therapy the mean TC level decreased significantly (from 8.09 mmol/L to 6.54 mmol/L) by 18.5%. In comparison with the results after placebo (the starting value), after the 8 weeks of the therapy the TC level reduction reached 22.4% and after 12 weeks 23.5%. The mean LDL @entity165 decreased by 26.1%, 30.8% and 32.9% after 4.8 and 12 weeks of @entity5753 treatment respectively. An increase in HDL @entity165 by 5.9%, 6.0% and 7.6% and decrease in @entity412 level by 10.7%, 14.9% and 14.0% respectively was also observed. In 6 @entity1 on @entity5753 treatment symptoms of acute @entity788 in 1 case, a @entity231 in 1 case and aggravation of @entity301 in 4 cases were noticed. These symptoms in the light of our knowledge of the mechanism of action of the drug used and of its side effects described in other trials, may be considered of independent on @entity5753 . The treatment was discontinued in 5 cases (because of gastrointestinal intolerance in 2 @entity1 , of aggravation of @entity301 in 2 @entity1 and of @entity158 in the right hypochondrium in 1 @entity1 who himself decided to stop the therapy).(ABSTRACT TRUNCATED AT 250 WORDS)
